High Tumor Grade in Salivary Gland Mucoepidermoid Carcinomas and Loss of Expression of Transforming Growth Factor β Receptor Type II | Head and Neck Cancer | JAMA Otolaryngology–Head & Neck Surgery | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.170.64.36. Please contact the publisher to request reinstatement.
1.
Pinkston  JACole  P Incidence rates of salivary gland tumors: results from a population-based study.  Otolaryngol Head Neck Surg.1999;120:834-840.Google Scholar
2.
Spiro  RHHuvos  AGBerk  RStrong  EW Mucoepidermoid carcinoma of salivary glands: a clinicopathologic study of 367 cases.  Am J Surg.1978;136:461-468.Google Scholar
3.
Goode  RKAuclair  PLEllis  GL Mucoepidermoid carcinoma of the major salivary glands: clinical and histopathologic analysis of 234 cases with evaluation of grading criteria.  Cancer.1998;82:1217-1224.Google Scholar
4.
Suzuki  MIchimiya  IMatsushita  FMogi  G Histological features and prognosis of patients with mucoepidermoid carcinoma of the parotid gland.  J Laryngol Otol.1998;112:944-947.Google Scholar
5.
Böttinger  EPLetterio  JJRoberts  AB Biology of TGF-beta in knockout and transgenic mouse models.  Kidney Int.1997;51:1355-1360.Google Scholar
6.
Moller  ASchwarz  ANeuner  PSchwarz  TLuger  TA Regulation of monocyte and keratinocyte interleukin 6 production by transforming growth factor beta.  Exp Dermatol.1994;3:314-320.Google Scholar
7.
Benefield  JPetruzzelli  GJFowler  STaitz  AKalkanis  JYoung  MR Regulation of the steps of angiogenesis by human head and neck squamous cell carcinomas.  Invasion Metastasis.1996;16:291-301.Google Scholar
8.
Shah  MForeman  DMFerguson  MWJ Neutralisation of TGF-beta1 and TGF-beta2 or exogenous addition of TGF-beta3 to cutaneous rat wounds reduces scarring.  J Cell Sci.1995;108:985-1002.Google Scholar
9.
Border  WANoble  NAYamamoto  T  et al Natural inhibitor of transforming growth factor beta protects against scarring in experimental kidney disease.  Nature.1992;360:361-364.Google Scholar
10.
Lagneaux  LDelforge  ABernier  MStryckmans  PBron  D TGF-beta activity and expression of its receptors in B-cell chronic lymphocytic leukemia.  Leuk Lymphoma.1998;31:99-106.Google Scholar
11.
Yu  WHeim  KQian  MSimmons-Menchaca  MSanders  BGKline  K Evidence for role of transforming growth factor-beta in RRR-alpha-tocopheryl succinate-induced apoptosis of human MDA-MB-435 breast cancer cells.  Nutr Cancer.1997;27:267-278.Google Scholar
12.
Yamamoto  MMaehara  YSakaguchi  YKusumoto  TIchiyoshi  YSugimachi  K Transforming growth factor-beta 1 induces apoptosis in gastric cancer cells through a p53-independent pathway.  Cancer.1996;77:1628-1633.Google Scholar
13.
Azuma  MYuki  TTamatani  TMotegi  KYoshida  HSato  M Lack of expression of transforming growth factor-beta type II receptor associated with malignant progression in human salivary gland clones.  Int J Cancer.1996;66:802-805.Google Scholar
14.
Gobbi  HArteaga  CLJensen  RA  et al Loss of expression of transforming growth factor beta type II receptor correlates with high tumour grade in human breast in-situ and invasive carcinomas.  Histopathology.2000;36:168-177.Google Scholar
15.
Tang  Bde Castro  KBarnes  HE  et al Loss of responsiveness to transforming growth factor beta induces malignant transformation of nontumorigenic rat prostate epithelial cells.  Cancer Res.1999;59:4834-4842.Google Scholar
16.
Guo  YKyprianou  N Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1–mediated apoptosis.  Cancer Res.1999;59:1366-1371.Google Scholar
17.
Sheng  HShao  JO'Mahony  CA  et al Transformation of intestinal epithelial cells by chronic TGF-beta1 treatment results in downregulation of the type II TGF-beta receptor and induction of cyclooxygenase-2.  Oncogene.1999;18:855-867.Google Scholar
18.
Lazzereschi  DRanieri  AMincione  GTaccogna  SNardi  FColletta  G Human malignant thyroid tumors displayed reduced levels of transforming growth factor beta receptor type II levels of transforming growth factor beta receptor type II messenger RNA and protein.  Cancer Res.1997;57:2071-2076.Google Scholar
19.
Kim  IYAhn  HJLang  S  et al Loss of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients.  Clin Cancer Res.1998;4:1625-1630.Google Scholar
Original Article
June 2001

High Tumor Grade in Salivary Gland Mucoepidermoid Carcinomas and Loss of Expression of Transforming Growth Factor β Receptor Type II

Author Affiliations

From the Departments of Otolaryngology–Head and Neck Surgery (Drs Dillard, Muller, and Del Gaudio) and Pathology and Laboratory Medicine (Drs Muller, Cohen, and Gal), and the School of Medicine (Dr Bloch), Emory University, Atlanta, Ga.

Arch Otolaryngol Head Neck Surg. 2001;127(6):683-686. doi:10.1001/archotol.127.6.683
Abstract

Background  Mucoepidermoid carcinoma (MEC) of salivary glands is a malignant, locally aggressive neoplasm with metastatic potential. The clinical course is usually dependent on histology; however, low-grade carcinomas can result in metastases and tumor-related death. Transforming growth factor β1 (TGF-β1) is a potent cytokine that affects growth inhibition of various cells and stimulates extracellular matrix production and angiogenesis. Loss of TGF-β receptor type II (TGF-β RII) expression has been related to resistance of TGF-β1–mediated growth control and tumor progression. In this study, we correlate MEC tumor grade with expression of TGF-β1 and TGF-β RII.

Design  Immunohistochemical staining was performed on 16 MEC specimens for activated forms of TGF-β1 and TGF-β RII. The percentage of cells in which staining yielded positive findings for activated TGF-β1 and TGF-β RII was correlated with tumor grade.

Results  Activated TGF-β1 was detected in 16 specimens (100%) of MEC and showed strong positive and diffuse staining. Predominately cytoplasmic staining of TGF-β1 was seen in salivary gland ducts, stroma, and endothelial cells. There was an inverse correlation between tumor grade and loss of expression of TGF-β RII. All low-grade MEC tumors yielded positive staining results, whereas only one case of intermediate-grade MEC had TGF-β RII expression. No high-grade MEC showed TGF-β RII expression.

Conclusions  Loss of expression of TGF-β RII correlates with tumor grade. The localization of activated TGF-β1 within neoplastic epithelium, tumor-associated stroma, and endothelium suggests that it might play a role in the stromal proliferation and/or angiogenesis associated with MEC.

×